Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Plicamycin

FDA-approved product (injectable, injection), marketed as Mithracin.

Registered studies
3
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Plicamycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other cytotoxic antibiotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Plicamycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Plicamycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

    NCT02859415 · start 2019-08-08

    Registered record
    Registry ID
    NCT02859415
    Conditions
    Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal
    Interventions
    Mithramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-08-08
    Completion
    2021-12-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms +1 more
    InterventionMithramycin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Mithramycin for Lung, Esophagus, and Other Chest Cancers

    NCT01624090 · start 2012-09-06

    Registered record
    Registry ID
    NCT01624090
    Conditions
    Lung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms; Breast Cancer
    Interventions
    Mithramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-09-06
    Completion
    2019-09-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms +1 more
    InterventionMithramycin
    PhasePhase 2
    Registry statusTerminated

  • Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

    NCT01610570 · start 2012-05-10

    Registered record
    Registry ID
    NCT01610570
    Conditions
    Ewing Sarcoma; Sarcoma
    Interventions
    Mithramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2012-05-10
    Completion
    2014-05-21
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing Sarcoma; Sarcoma
    InterventionMithramycin
    PhasePhase 1 / Phase 2
    Registry statusTerminated